Halozyme Delivers Record Quarter, Raises Outlook, and Wins Wall Street Praise
Strong Q2 for Halozyme: Revenue $481M (+48% YoY), royalties +50%. Raises 2026 guidance. H.C. Wainwright, Leerink, Morgan Stanley upgrade.
/ 4 items
#HALO↓
Goldman Sachs Downgrades Halozyme to Sell
HALO faces a post-2030 royalty cliff; Goldman Sachs cuts rating to Sell with $56 target, citing long-term revenue risks.
Halozyme Gets Upgrade as Medicare Impact Fears Ease
Leerink upgrades Halozyme to Market Perform after company reveals only 20% of ENHANZE sales come from Medicare Part B, significantly less than feared. Price target remains $70.
Halozyme is Set to Acquire Elektrofi in a Deal Worth up to $900M, Expanding its Lineup of Drug Delivery Products
Halozyme is buying Elektrofi ($900M) for Hypercon tech. This innovation concentrates powerful biologic drugs for small, easy shots. This means patients can use auto-injectors at home, boosting convenience and treatment access.